糖尿病視網膜病變市場 - 成長，趨勢，預測
Diabetic Retinopathy Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921276|
|出版日期||內容資訊||英文 113 Pages
|糖尿病視網膜病變市場 - 成長，趨勢，預測 Diabetic Retinopathy Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 113 Pages||
Global Diabetic Retinopathy market is expected to witness a CAGR of 11.5% during the forecast period. Certain factors that are driving the market growth include the rising prevalence of diabetes and blindness due to the same, growing geriatric population base, increasing technological advancements in diabetic retinopathy surgical instruments.
Diabetic retinopathy (DR) is a leading cause of vision-loss globally. According to a 2015 article, titled "Epidemiology of diabetic retinopathy, diabetic macular edema, and related vision loss", out of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one-third of DR is vision-threatening DR. The most clinically important risk factors for progression to vision loss include duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR. Hence, the rising prevalence of DR, along with the growing awareness and concern over it, are expected to drive the market growth over the forecast period.
Diabetic retinopathy refers to a diabetes complication that affects eyes, DR results in damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Initially, diabetic retinopathy may cause no symptoms or only mild vision problems. But eventually, it can cause blindness.
Proliferative diabetic retinopathy is Expected to Hold Significant Market Share in the Type Segment
Proliferative diabetic retinopathy (PDR): PDR is the most advanced stage of diabetic retinopathy. At this stage, circulation problems deprive the retina of oxygen. As a result, new, fragile blood vessels can begin to grow in the retina and into the vitreous, the gel-like fluid that fills the back of the eye. The new blood vessels may leak blood into the vitreous, clouding vision. Symptoms include progressive loss of vision, particularly in those who are not properly followed or treated. The major risk factors for PDR include the duration of diabetes, since 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of PDR.
North America Dominates the Market and Expected to do Same in the Forecast Period
Over the past decade, the prevalence of diabetes in North America has increased. People with diabetes are at risk for diabetic retinopathy. Diabetic retinopathy is the leading cause of new cases of blindness among adults aged 20 to 74 years in the United States. More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report published by the Centers for Disease Control and Prevention (CDC). The report finds that as of 2015, 30.3 million Americans - 9.4 percent of the U.S. population -have diabetes. Hence, all these factors are expected to contribute to market growth across the entire region.
The global Diabetic Retinopathy market is moderately competitive and consists of a few major players. Companies like Alimera Sciences, Allergan plc, BCN Peptides, Genentech, Glycadia Pharmaceuticals, Kowa Group, Novartis AG, Oxurion NV., Regeneron Pharmaceuticals Inc, among others, which hold the substantial market share in the Diabetic Retinopathy market.